Prediction of Hepatic Metabolic Clearance

ObjectiveTo perform a comparative quantitative evaluation of the prediction accuracy for human hepatic metabolic clearance of 5 different mathematical models: allometric scaling (multiple species and rat only), physiologically based direct scaling, empirical in vitro-in vivo correlation, and supervised artificial neural networks.MethodsThe mathematical prediction models were implemented with a publicly available dataset of 22 extensively metabolised compounds and compared for their prediction accuracy using 3 quality indicators: prediction error sum of squares (PRESS), r2 and the fold-error.ResultsApproaches such as physiologically based direct scaling, empirical in vitro-in vivo correlation and artificial neural networks, which are based on in vitro data only, yielded an average fold-error ranging from 1.64 to 2.03 and r2 values greater than 0.77, as opposed to r2 values smaller than 0.44 when using allometric scaling combining in vivo and in vitro preclinical data. The percentage of successful predictions (less than 2-fold error) ranged from 55% (rat allometric scaling) to between 64 and 68% with the other approaches.ConclusionsOn the basis of a diverse set of 22 metabolised drug molecules, these studies showed that the most cost-effective and accurate approaches, such as physiologically based direct scaling and empirical in vitro-in vivo correlation, are based on in vitro data alone. Inclusion of in vivo preclinical data did not significantly improve prediction accuracy; the prediction accuracy of the allometric approaches was at the lower end of all methods compared.

[1]  J B Houston,et al.  In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[2]  I. Helland Partial least squares regression and statistical models , 1990 .

[3]  A. A. Mullin,et al.  Principles of neurodynamics , 1962 .

[4]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[5]  D. Campbell Can Allometric Interspecies Scaling be Used to Predict Human Kinetics? , 1994 .

[6]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[7]  H Boxenbaum,et al.  First‐Time‐in‐Human Dose Selection: Allometric Thoughts and Perspectives , 1995, Journal of clinical pharmacology.

[8]  H Boxenbaum,et al.  Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. , 1984, Drug metabolism reviews.

[9]  A. Höskuldsson PLS regression methods , 1988 .

[10]  R C Chou,et al.  Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. , 1997, Journal of pharmaceutical sciences.

[11]  Y. Sugiyama,et al.  Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. , 1997, The Journal of pharmacology and experimental therapeutics.

[12]  L. Gleser Measurement, Regression, and Calibration , 1996 .

[13]  J V Gobburu,et al.  Artificial neural networks as a novel approach to integrated pharmacokinetic-pharmacodynamic analysis. , 1996, Journal of pharmaceutical sciences.

[14]  Y. Sugiyama,et al.  Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. , 1997, The Journal of pharmacology and experimental therapeutics.

[15]  Brian D. Ripley,et al.  Pattern Recognition and Neural Networks , 1996 .

[16]  A. Polak,et al.  Combination therapy in systemic mycosis. , 1990, Journal of chemotherapy.

[17]  P. Garthwaite An Interpretation of Partial Least Squares , 1994 .

[18]  Christopher M. Bishop,et al.  Neural networks for pattern recognition , 1995 .

[19]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[20]  T Lavé,et al.  Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. , 1999, Journal of medicinal chemistry.

[21]  T Lavé,et al.  Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations , 1999, Clinical pharmacokinetics.

[22]  R. Palmer,et al.  Introduction to the theory of neural computation , 1994, The advanced book program.

[23]  T Iwatsubo,et al.  PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.

[24]  M. Bayliss,et al.  Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  G Reibnegger,et al.  Neural networks as a tool for utilizing laboratory information: comparison with linear discriminant analysis and with classification and regression trees. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[27]  D. Cross,et al.  A COMMENTARY ON THE USE OF HEPATOCYTES IN DRUG METABOLISM STUDIES DURING DRUG DISCOVERY AND DEVELOPMENT* , 2000, Drug metabolism reviews.

[28]  J B Houston,et al.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.

[29]  T. Izumi,et al.  Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. , 1996, The Journal of pharmacology and experimental therapeutics.

[30]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[31]  R. Erb,et al.  The Backpropagation Neural Network — A Bayesian Classifier , 1995, Clinical pharmacokinetics.

[32]  Sam Kash Kachigan Multivariate statistical analysis: A conceptual introduction , 1982 .

[33]  G Schneider,et al.  Artificial neural networks for computer-based molecular design. , 1998, Progress in biophysics and molecular biology.

[34]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[35]  John H. Mathews,et al.  Numerical Methods For Mathematics, Science, and Engineering , 1987 .

[36]  J. Mordenti,et al.  Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.

[37]  D. Jaeck,et al.  Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.